合同研究、開發和(he)生(sheng)產（CRDMO）公(gong)(gong)(gong)司藥(yao)(yao)(yao)明(ming)生(sheng)物宣(xuan)布子公(gong)(gong)(gong)司無錫(xi)藥(yao)(yao)(yao)明(ming)生(sheng)物技術(shu)股(gu)份(fen)有(you)(you)限(xian)公(gong)(gong)(gong)司已(yi)于10月(yue)(yue)7日正式從美(mei)國(guo)商務(wu)部的"未(wei)核實(shi)清(qing)單"（UVL）中(zhong)移(yi)除。今年2月(yue)(yue)，藥(yao)(yao)(yao)明(ming)生(sheng)物兩家子公(gong)(gong)(gong)司 -- 無錫(xi)藥(yao)(yao)(yao)明(ming)生(sheng)物技術(shu)股(gu)份(fen)有(you)(you)限(xian)公(gong)(gong)(gong)司和(he)上(shang)海藥(yao)(yao)(yao)明(ming)生(sheng)物技術(shu)有(you)(you)限(xian)公(gong)(gong)(gong)司（WuXi Biologics (Shanghai) Co., Ltd.）由于美(mei)國(guo)針(zhen)對部分出口產品(pin)用(yong)途(tu)核實(shi)延期而被列入UVL。6月(yue)(yue)，無錫(xi)藥(yao)(yao)(yao)明(ming)生(sheng)物技術(shu)股(gu)份(fen)有(you)(you)限(xian)公(gong)(gong)(gong)司在中(zhong)國(guo)商務(wu)部的協調下(xia)成功(gong)完(wan)成了美(mei)國(guo)商務(wu)部的最終用(yong)戶(hu)訪問。(醫藥(yao)(yao)(yao)健聞)